Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
2019; Massachusetts Medical Society; Volume: 381; Issue: 25 Linguagem: Inglês
10.1056/nejmoa1911361
ISSN1533-4406
AutoresIsabelle Ray‐Coquard, Patricia Pautier, Sandro Pignata, David Pérol, Antonio González‐Martín, Regina Berger, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Johanna Mäenpää, Frédèric Selle, Jalid Sehouli, Domenica Lorusso, Eva Maria Guerra Alía, Alexander Reinthaller, Shoji Nagao, Claudia Lefeuvre‐Plesse, Ulrich Canzler, Giovanni Scambia, Alain Lortholary, Frederik Marmé, Pierre Combe, Nikolaus de Gregorio, Manuel Rodrigues, Paul Buderath, Coraline Dubot, Alexander Burges, Benoît You, Éric Pujade-Lauraine, Philipp Harter,
Tópico(s)Toxin Mechanisms and Immunotoxins
ResumoOlaparib has shown significant clinical benefit as maintenance therapy in women with newly diagnosed advanced ovarian cancer with a BRCA mutation. The effect of combining maintenance olaparib and bevacizumab in patients regardless of BRCA mutation status is unknown.
Referência(s)